The Food and Drug Administration (FDA) announced on Tuesday that it had just approved the first-ever treatment for thyroid eye disease (TED), Tepezza, which is developed by Horizon Therapeutics (NASDAQ: HZNP).
Thyroid eye disease, also known as Graves' ophthalmopathy, is a rare disease that, according to some sources, affects as many as 42 people per 100,000 every year. This rare condition causes the tissues behind the eye to become inflamed, which results in the eye becoming red and swollen, and causes severe problems such as double vision.
Image source: Getty Images.
In addition to receiving approval to treat TED, Tepezza also received Priority Review, Orphan Drug, Fast Track, and Breakthrough Therapy designations from the agency.
A big deal for a rare disease
Previous clinical trial results for Tepezza include a phase 2 trial done in 2017, as well as a more recent phase 3 trial. The latter trial saw a significant improvement in patients with TED in comparison to the placebo, with symptoms of the condition -- such as double vision -- seeing a significant reduction in severity.
Tepezza was the subject of an FDA advisory committee meeting back in December, with the committee voting unanimously in favor of Tepezza's approval. Although the pharmaceutical company has received approval alongside a slew of designations from the agency following the decision, Horizon will still conduct a post-marketing study on a larger patient population to further evaluate the safety of the drug. The most common side effects include muscle spasms and nausea, which were relatively mild during the clinical trials.
10 stocks we like better than Horizon Pharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Horizon Pharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of December 1, 2019
Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
